Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Behrens

Showing results (51-60 of 119) with videos related to

Pageof 12
Sort By:
Arthritis Care & Research|April 24, 2013
Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritisFrank Behrens, Hans-Peter Tony, Rieke Alten, et al.
Rheumatology (Oxford, England)|October 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 studyLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
Rheumatology (Oxford, England)|July 28, 2018
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2Mark C Genovese, Benard Combe, Joel M Kremer, et al.
RMD Open|March 10, 2023
Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpAAnne Constanze Regierer, Anja Weiß, Fabian Proft, et al.
The Journal of Rheumatology|October 15, 2025
Predicting treatment outcomes in patients with psoriatic arthritis or axial spondyloarthritis: An artificial intelligence-driven approachAsmir Vodenčarević, Jan Brandt-Jürgens, Sara Bär, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|August 21, 2021
[Treatment of psoriasis with secukinumab : Practical guidance]Andreas Körber, Matthias Augustin, Frank Behrens, et al.
Arthritis Research & Therapy|July 8, 2021
Implementing an automated monitoring process in a digital, longitudinal observational cohort studyLisa Lindner, Anja Weiß, Andreas Reich, et al.
Clinical and Experimental Rheumatology|January 9, 2023
Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational studyFrank Behrens, Gerd-Rudiger Burmester, Michael W Hofmann, et al.
Clinical and Experimental Rheumatology|May 18, 2021
Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily careFrank Behrens, Gerd-Rüdiger Burmester, Martin Feuchtenberger, et al.
Annals of the Rheumatic Diseases|December 16, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trialLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
Pageof 12

Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Arthritis Care & Research|April 24, 2013
Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritisFrank Behrens, Hans-Peter Tony, Rieke Alten, et al.
Rheumatology (Oxford, England)|October 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 studyLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
Rheumatology (Oxford, England)|July 28, 2018
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2Mark C Genovese, Benard Combe, Joel M Kremer, et al.
RMD Open|March 10, 2023
Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpAAnne Constanze Regierer, Anja Weiß, Fabian Proft, et al.
The Journal of Rheumatology|October 15, 2025
Predicting treatment outcomes in patients with psoriatic arthritis or axial spondyloarthritis: An artificial intelligence-driven approachAsmir Vodenčarević, Jan Brandt-Jürgens, Sara Bär, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|August 21, 2021
[Treatment of psoriasis with secukinumab : Practical guidance]Andreas Körber, Matthias Augustin, Frank Behrens, et al.
Arthritis Research & Therapy|July 8, 2021
Implementing an automated monitoring process in a digital, longitudinal observational cohort studyLisa Lindner, Anja Weiß, Andreas Reich, et al.
Clinical and Experimental Rheumatology|January 9, 2023
Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational studyFrank Behrens, Gerd-Rudiger Burmester, Michael W Hofmann, et al.
Clinical and Experimental Rheumatology|May 18, 2021
Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily careFrank Behrens, Gerd-Rüdiger Burmester, Martin Feuchtenberger, et al.
Annals of the Rheumatic Diseases|December 16, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trialLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
Pageof 12